297 related articles for article (PubMed ID: 32249614)
1. Beneficial effect on podocyte number in experimental diabetic nephropathy resulting from combined atrasentan and RAAS inhibition therapy.
Hudkins KL; Wietecha TA; Steegh F; Alpers CE
Am J Physiol Renal Physiol; 2020 May; 318(5):F1295-F1305. PubMed ID: 32249614
[TBL] [Abstract][Full Text] [Related]
2. Reversibility of structural and functional damage in a model of advanced diabetic nephropathy.
Pichaiwong W; Hudkins KL; Wietecha T; Nguyen TQ; Tachaudomdach C; Li W; Askari B; Kobayashi T; O'Brien KD; Pippin JW; Shankland SJ; Alpers CE
J Am Soc Nephrol; 2013 Jun; 24(7):1088-102. PubMed ID: 23641056
[TBL] [Abstract][Full Text] [Related]
3. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes.
Deb DK; Sun T; Wong KE; Zhang Z; Ning G; Zhang Y; Kong J; Shi H; Chang A; Li YC
Kidney Int; 2010 Jun; 77(11):1000-9. PubMed ID: 20182412
[TBL] [Abstract][Full Text] [Related]
4. Regression of diabetic nephropathy by treatment with empagliflozin in BTBR ob/ob mice.
Hudkins KL; Li X; Holland AL; Swaminathan S; Alpers CE
Nephrol Dial Transplant; 2022 Apr; 37(5):847-859. PubMed ID: 34865099
[TBL] [Abstract][Full Text] [Related]
5. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice.
Inoki K; Mori H; Wang J; Suzuki T; Hong S; Yoshida S; Blattner SM; Ikenoue T; Rüegg MA; Hall MN; Kwiatkowski DJ; Rastaldi MP; Huber TB; Kretzler M; Holzman LB; Wiggins RC; Guan KL
J Clin Invest; 2011 Jun; 121(6):2181-96. PubMed ID: 21606597
[TBL] [Abstract][Full Text] [Related]
6. Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist.
Zhang Y; Deb DK; Kong J; Ning G; Wang Y; Li G; Chen Y; Zhang Z; Strugnell S; Sabbagh Y; Arbeeny C; Li YC
Am J Physiol Renal Physiol; 2009 Sep; 297(3):F791-801. PubMed ID: 19535571
[TBL] [Abstract][Full Text] [Related]
7. Reduced Glomerular Endothelial Thrombomodulin Is Associated with Glomerular Macrophage Infiltration in Diabetic Nephropathy.
van Aanhold CCL; Dijkstra KL; Bos M; Wolterbeek R; van den Berg BM; Bruijn JA; Bajema IM; Baelde HJ
Am J Pathol; 2021 May; 191(5):829-837. PubMed ID: 33617784
[TBL] [Abstract][Full Text] [Related]
8. Automated image analysis of a glomerular injury marker desmin in spontaneously diabetic Torii rats treated with losartan.
Kakimoto T; Okada K; Hirohashi Y; Relator R; Kawai M; Iguchi T; Fujitaka K; Nishio M; Kato T; Fukunari A; Utsumi H
J Endocrinol; 2014 Jul; 222(1):43-51. PubMed ID: 24781258
[TBL] [Abstract][Full Text] [Related]
9. Effect of angiotensin II type 1 receptor blocker on 12-lipoxygenase activity and slit diaphragm protein expression in type 2 diabetic rat glomeruli.
Xu HZ; Wang WN; Zhang YY; Cheng YL; Xu ZG
J Nephrol; 2016 Dec; 29(6):775-782. PubMed ID: 27021232
[TBL] [Abstract][Full Text] [Related]
10. Mangiferin prevents diabetic nephropathy progression and protects podocyte function via autophagy in diabetic rat glomeruli.
Wang X; Gao L; Lin H; Song J; Wang J; Yin Y; Zhao J; Xu X; Li Z; Li L
Eur J Pharmacol; 2018 Apr; 824():170-178. PubMed ID: 29444469
[TBL] [Abstract][Full Text] [Related]
11. Grem2 mediates podocyte apoptosis in high glucose milieu.
Wen H; Kumar V; Mishra A; Song S; Aslam R; Hussain A; Wang H; Zhou X; He X; Wu G; Luo H; Lan X; Malhotra A; Singhal PC
Biochimie; 2019 May; 160():113-121. PubMed ID: 30831151
[TBL] [Abstract][Full Text] [Related]
12. Impaired Podocyte Autophagy Exacerbates Proteinuria in Diabetic Nephropathy.
Tagawa A; Yasuda M; Kume S; Yamahara K; Nakazawa J; Chin-Kanasaki M; Araki H; Araki S; Koya D; Asanuma K; Kim EH; Haneda M; Kajiwara N; Hayashi K; Ohashi H; Ugi S; Maegawa H; Uzu T
Diabetes; 2016 Mar; 65(3):755-67. PubMed ID: 26384385
[TBL] [Abstract][Full Text] [Related]
13. Diabetic kidney lesions of GIPRdn transgenic mice: podocyte hypertrophy and thickening of the GBM precede glomerular hypertrophy and glomerulosclerosis.
Herbach N; Schairer I; Blutke A; Kautz S; Siebert A; Göke B; Wolf E; Wanke R
Am J Physiol Renal Physiol; 2009 Apr; 296(4):F819-29. PubMed ID: 19211686
[TBL] [Abstract][Full Text] [Related]
14. Renin-Angiotensin-Aldosterone System Inhibition Increases Podocyte Derivation from Cells of Renin Lineage.
Lichtnekert J; Kaverina NV; Eng DG; Gross KW; Kutz JN; Pippin JW; Shankland SJ
J Am Soc Nephrol; 2016 Dec; 27(12):3611-3627. PubMed ID: 27080979
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of podocyte lesion in patients with diabetic nephropathy: Wilms' tumor-1 protein used as a podocyte marker.
Su J; Li SJ; Chen ZH; Zeng CH; Zhou H; Li LS; Liu ZH
Diabetes Res Clin Pract; 2010 Feb; 87(2):167-75. PubMed ID: 19969384
[TBL] [Abstract][Full Text] [Related]
16. Selective phosphodiesterase-5 (PDE-5) inhibitor vardenafil ameliorates renal damage in type 1 diabetic rats by restoring cyclic 3',5' guanosine monophosphate (cGMP) level in podocytes.
Fang L; Radovits T; Szabó G; Mózes MM; Rosivall L; Kökény G
Nephrol Dial Transplant; 2013 Jul; 28(7):1751-61. PubMed ID: 23203993
[TBL] [Abstract][Full Text] [Related]
17. Effects of angiotensin receptor blocker on phenotypic alterations of podocytes in early diabetic nephropathy.
Dai HY; Zheng M; Tang RN; Ni J; Ma KL; Li Q; Liu BC
Am J Med Sci; 2011 Mar; 341(3):207-14. PubMed ID: 21326079
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD).
Andress DL; Coll B; Pritchett Y; Brennan J; Molitch M; Kohan DE
Life Sci; 2012 Oct; 91(13-14):739-42. PubMed ID: 22326504
[TBL] [Abstract][Full Text] [Related]
19. Prevention of the progression of renal injury in diabetic rodent models with preexisting renal disease with chronic endothelin A receptor blockade.
Spires D; Poudel B; Shields CA; Pennington A; Fizer B; Taylor L; McPherson KC; Cornelius DC; Williams JM
Am J Physiol Renal Physiol; 2018 Oct; 315(4):F977-F985. PubMed ID: 29846112
[TBL] [Abstract][Full Text] [Related]
20. ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy.
Gross ML; El-Shakmak A; Szábó A; Koch A; Kuhlmann A; Münter K; Ritz E; Amann K
Diabetologia; 2003 Jun; 46(6):856-68. PubMed ID: 12802493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
